MA35086B1 - Compose de triazolopyridine - Google Patents

Compose de triazolopyridine

Info

Publication number
MA35086B1
MA35086B1 MA36027A MA36027A MA35086B1 MA 35086 B1 MA35086 B1 MA 35086B1 MA 36027 A MA36027 A MA 36027A MA 36027 A MA36027 A MA 36027A MA 35086 B1 MA35086 B1 MA 35086B1
Authority
MA
Morocco
Prior art keywords
triazolopyridine
compound
formula
relates
triazolopyridine compounds
Prior art date
Application number
MA36027A
Other languages
English (en)
Inventor
Alexander Flohr
Luca Gobbi
Zbinden Katrin Groebke
Matthias Koerner
Jens-Uwe Peters
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA35086B1 publication Critical patent/MA35086B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne des composés de triazolopyridine de formule (i), dans laquelle r
MA36027A 2010-12-07 2013-06-20 Compose de triazolopyridine MA35086B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10194014 2010-12-07
PCT/EP2011/071685 WO2012076430A1 (fr) 2010-12-07 2011-12-05 Composés de triazolopyridine

Publications (1)

Publication Number Publication Date
MA35086B1 true MA35086B1 (fr) 2014-05-02

Family

ID=45099086

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36027A MA35086B1 (fr) 2010-12-07 2013-06-20 Compose de triazolopyridine

Country Status (30)

Country Link
US (1) US8349824B2 (fr)
EP (1) EP2649070B1 (fr)
JP (1) JP5932828B2 (fr)
KR (1) KR20130128426A (fr)
CN (1) CN103237803B (fr)
AR (1) AR084152A1 (fr)
AU (1) AU2011340685A1 (fr)
BR (1) BR112013013912A2 (fr)
CA (1) CA2816829C (fr)
CL (1) CL2013001591A1 (fr)
CO (1) CO6741154A2 (fr)
CR (1) CR20130239A (fr)
CY (1) CY1115863T1 (fr)
DK (1) DK2649070T3 (fr)
EA (1) EA022607B1 (fr)
EC (1) ECSP13012667A (fr)
ES (1) ES2520647T3 (fr)
HR (1) HRP20141200T1 (fr)
IL (1) IL225969A0 (fr)
MA (1) MA35086B1 (fr)
MX (1) MX2013006054A (fr)
PE (1) PE20140226A1 (fr)
PL (1) PL2649070T3 (fr)
PT (1) PT2649070E (fr)
RS (1) RS53677B1 (fr)
SG (1) SG190305A1 (fr)
SI (1) SI2649070T1 (fr)
UA (1) UA109037C2 (fr)
WO (1) WO2012076430A1 (fr)
ZA (1) ZA201303811B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140235667A1 (en) 2011-09-22 2014-08-21 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
WO2013043520A1 (fr) 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Composés triazolopyridyle à utiliser en tant qu'inhibiteurs de l'aldostérone synthase
WO2013117610A1 (fr) 2012-02-09 2013-08-15 F. Hoffmann-La Roche Ag Procédé de préparation de dérivés de 2-phényl-[1,2,4]triazolo[1,5-a] pyridine
JP2016513083A (ja) * 2013-01-31 2016-05-12 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 放射標識された化合物
EP2963037B1 (fr) 2013-02-27 2019-03-27 Mochida Pharmaceutical Co., Ltd. Nouveau dérivé de pyrazole
RU2663834C2 (ru) 2013-04-30 2018-08-10 Ф. Хоффманн-Ля Рош Аг Катализируемое палладием сочетание пиразоламидов
US9708314B2 (en) * 2013-05-31 2017-07-18 Nissan Chemical Industries, Ltd. Heterocyclic amide compound
WO2015006689A1 (fr) 2013-07-12 2015-01-15 University Of South Alabama Traitement et diagnostic du cancer et d'états précancéreux à l'aide d'inhibiteurs de pde10a et procédés pour mesurer l'expression de pde10a
JP6568855B2 (ja) * 2014-07-30 2019-08-28 持田製薬株式会社 ピラゾール誘導体の製造方法
CN107074844A (zh) * 2014-07-30 2017-08-18 持田制药株式会社 吡唑衍生物的制造方法
WO2020021024A1 (fr) * 2018-07-26 2020-01-30 Phenex Pharmaceuticals Ag Composés bicycliques substitués en tant que modulateurs du récepteur d'hydrocarbures aryle (ahr)
BR112022024751A2 (pt) 2020-06-05 2023-03-07 Noema Pharma Ag Uso de um inibidor de fosfodiesterase 10 para o tratamento da síndrome de tourette
AU2022214289A1 (en) * 2021-01-28 2023-08-10 Noema Pharma Ag Methods for the treatment of childhood-onset fluency disorder

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032404A1 (en) 2003-07-31 2007-02-08 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
TWI501965B (zh) 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物

Also Published As

Publication number Publication date
CN103237803B (zh) 2016-04-13
IL225969A0 (en) 2013-06-27
DK2649070T3 (da) 2014-10-13
CO6741154A2 (es) 2013-08-30
ECSP13012667A (es) 2013-08-30
CR20130239A (es) 2013-06-27
MX2013006054A (es) 2013-06-18
ZA201303811B (en) 2014-04-30
EP2649070B1 (fr) 2014-09-17
ES2520647T3 (es) 2014-11-11
JP5932828B2 (ja) 2016-06-08
UA109037C2 (uk) 2015-07-10
PE20140226A1 (es) 2014-03-08
WO2012076430A1 (fr) 2012-06-14
BR112013013912A2 (pt) 2016-09-13
CA2816829C (fr) 2018-12-04
CN103237803A (zh) 2013-08-07
CA2816829A1 (fr) 2012-06-14
EP2649070A1 (fr) 2013-10-16
US20120142665A1 (en) 2012-06-07
SG190305A1 (en) 2013-06-28
CY1115863T1 (el) 2017-01-25
SI2649070T1 (sl) 2014-12-31
JP2013544859A (ja) 2013-12-19
PT2649070E (pt) 2014-11-21
AR084152A1 (es) 2013-04-24
RS53677B1 (en) 2015-04-30
HRP20141200T1 (hr) 2015-02-13
US8349824B2 (en) 2013-01-08
PL2649070T3 (pl) 2015-03-31
KR20130128426A (ko) 2013-11-26
EA201390799A1 (ru) 2013-12-30
EA022607B1 (ru) 2016-01-29
AU2011340685A1 (en) 2013-05-23
CL2013001591A1 (es) 2013-12-27

Similar Documents

Publication Publication Date Title
MA35086B1 (fr) Compose de triazolopyridine
MA35926B1 (fr) Pyrrolidine-2-carboxamides substitués
MA35049B1 (fr) Triazolopyridines
MA35089B1 (fr) Inhibiteurs de la production de leucotrienes de type benzodioxane
MA37940A2 (fr) Nouveaux dérivés bicycliques
MA35357B1 (fr) Composes de type anilines
MA35664B1 (fr) Nouveaux dérivés bicycliques de la dihydroisoquinoline-1-one
MA37519A1 (fr) Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1
MA35245B1 (fr) Pyridin-2-amides utiles comme agonistes de cb2
MA35452B1 (fr) 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
CR20120295A (es) Triazolopiridinas
MA34644B1 (fr) Dérivés de pyrazole aminopyrimidine en tant que modulateurs du lrrk2
CO6852084A2 (es) Nuevos compuestos sustituidos con halógeno
MX350892B (es) Síntesis de compuesto antiviral.
CR20130129A (es) Anàlogos de buprenorfina
AU2014270524A8 (en) 2-phenylimidazo [1,2-a]pyrimidines as imaging agents
AU2011232516A8 (en) Chemical compounds
MA34389B1 (fr) Nouvelles aminopyrazoloquinazolines
MA38645A1 (fr) Nouveaux inhibiteurs de cyp17/antiandrogènes
CR20120637A (es) Triazolopiridinas sustituidas
MA37686A1 (fr) Composés phénoxyéthyl pipéridine
PA8792101A1 (es) Nuevo procedimiento de sintesis del ( 7-metoxi-1- naftil) aceto
MA34578B1 (fr) Composés de tétrahydrofuranyl disubstitués en tant qu'antagonistes du récepteur de la bradykinine b1
CR20130041A (es) ISOXAZOLO[5,4-b]PIRIDINAS HERBICIDAS